JAMA: Tralokinumab is a safe and efficient treatment for atopic dermatitis.

Published Date: 28 Apr 2023

According to a recent study in the Journal of the American Medical Association, when used to treat adolescents with moderate to severe atopic dermatitis.

Read Full News

Latest News

US FDA Approves Regeneron's Rare Bone Disorder Drug

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder ⁠after it significantly reduced abnormal bone formation in certain soft...

Ebola Spreading Exponentially in Congo as Death Toll Tops 2,500, UN Says

More than 2,500 people have now died in the Democratic Republic of Congo's Ebola outbreak, which is spreading exponentially in an area larger ⁠than France, senior United...

Dual Targeted Therapy May Be Beneficial in Refractory PsA

Combining two advanced targeted therapies appears feasible in patients with psoriatic arthritis and may deliver symptom improvement with few mild side effects.

Skin Apps Didn't Move the Cancer Needle

Presented at EADO Congress 2026, a Dutch RCT found skin cancer app access didn't improve cancer detection at 12 months, but it did drive more benign lesion visits.

HPV Vaccination Underutilized in Transplant Recipients

HPV vaccination rates were low among solid organ transplant recipients, a study shows.

Navigating GLP-1 Hair Loss With Your Patients

Patients are increasingly anxious about hair shedding on GLP-1s. Here is what the latest research shows, why it happens, and how to manage it in the clinic.

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Latest News

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder ⁠after it significantly reduced abnormal bone formation in certain soft...

More than 2,500 people have now died in the Democratic Republic of Congo's Ebola outbreak, which is spreading exponentially in an area larger ⁠than France, senior United...

Combining two advanced targeted therapies appears feasible in patients with psoriatic arthritis and may deliver symptom improvement with few mild side effects.

Presented at EADO Congress 2026, a Dutch RCT found skin cancer app access didn't improve cancer detection at 12 months, but it did drive more benign lesion visits.

HPV vaccination rates were low among solid organ transplant recipients, a study shows.

Patients are increasingly anxious about hair shedding on GLP-1s. Here is what the latest research shows, why it happens, and how to manage it in the clinic.

News All Time

Topical Finasteride Effective for Hair Loss in Men

Topical finasteride 0.25% monotherapy demonstrates sustained effectiveness and a favourable safety profile in men with androgenetic alopecia over 52 weeks.

Povorcitinib Beneficial for HS in Phase 3 Studies

According to new phase 3 trial results, povorcitinib, a JAK1 inhibitor, could provide an oral alternative to injectable biologics for patients with hidradenitis suppurativa.

Upadacitinib Effective for Severe Alopecia Areata

Once-daily upadacitinib significantly improves scalp hair regrowth and quality of life vs placebo in adults and adolescents with severe alopecia areata.

Lilly Sues Six Companies Over Alleged Illegal Sales Of Experimental Obesity Drug Retatrutide

Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of ⁠its experimental obesity drug...

Can Apremilast Curb PsA in Patients With Psoriasis?

A 24-week course of the phosphodiesterase 4 inhibitor apremilast may ease skin symptoms and joint tenderness while keeping early bone changes stable in high-risk patients with psoriasis.

WHO Defends Immunisation Schedules After Trump Orders Fewer Childhood Shots

The World Health Organization on Tuesday defended the science-based process used to determine childhood immunisation schedules after U.S. President Donald Trump signed an...

Trump Order Reduces US Vaccine Schedule, Seeks to Split MMR Shot

U.S. President Donald Trump signed an executive order on Monday calling for fewer childhood vaccinations by limiting the inoculation schedule to 11 immunizations, which he...

Pancreatic Cancer Specialists Getting a Jump on Daraxonrasib

In the wake of striking survival data, more than 2000 US patients are receiving daraxonrasib before FDA approval.

Alopecia in Transgender Patients: Management Strategies

Low-dose oral minoxidil ranks high as a first-line alopecia treatment option for transmasculine individuals and, especially in combination with spironolactone, for transfeminine patients.

Wellness Peptides Are Trending: Are They Safe?

Growing interest in unapproved peptides is raising concerns about weak human evidence, uncertain product quality, self-administration, and poorly understood long-term safety.

Skin Cancer Prevention Gaps Seen in Indigenous Adults

A survey of American Indian/Alaska Native adults in South Dakota finds low sunscreen use and gaps in skin cancer risk perception and knowledge.

Hemangiomas: Absence of One Feature May Rule Out Syndrome

A systematic review of patients with LUMBAR syndrome found that the anatomic midline was involved in all cases, raising the possibility that this is a diagnostic criterion.

Hyperinsulinemic Hypoglycemia: Looking Beyond Insulinoma?

A distinctive metabolic signature may identify rare insulin receptor disorders earlier, helping clinicians avoid unnecessary insulinoma investigations.

FDA Approves Replimune Skin Cancer Drug After Rejections

The accelerated approval follows FDA concerns about the single-arm evidence supporting the treatment.

TikTok Turns Isotretinoin Into a Beauty Trend

Social media has fueled new demand for isotretinoin, but the drug’s true value and its best-known risks remain defined by evidence, not influencer hype.

Manufacturer Files for Botox Approval for Jawline Contouring

After positive findings from phase 3 trials, Allergan Aesthetics submits sBLA to the FDA for onabotulinumtoxinA, to improve the appearance of the masseter muscle.

Recommended News For You

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

Novel Psychedelic Promising on Resistant Depression

Chronic pain and poor sleep are troublesome bed partners.

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

Recommended Articles For You

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection? 

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

Evolution of Cancer Care Through Developmental Therapeutics 

Understanding Vaso Occlusive Crisis: Symptoms, Causes, and Management Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

AI catches one-third of interval breast cancers missed at screening

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

1.

Lymphomatoid Papulosis: What You Need to Know

2.

Exploring the Potential of Cytologic Atypia in Cancer Diagnosis

3.

The Rise of Immunotherapy: New Advances in Cancer Treatment

4.

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research

5.

Patient Management Following Organ-Preserving Cancer Interventions

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

3.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

4.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot